Data at the 2022 ASCO Annual Meeting Highlight Genentech’s Continued Commitment to Innovation in Oncology and Personalized Healthcare
– Pivotal data on glofitamab, a potential first-in-class CD20xCD3 T-cell engaging bispecific antibody in heavily pre-treated patients with aggressive lymphoma, will be presented as part of our industry-leading hematology portfolio – – Further studies exploring broad genomic testing to support informed treatment decisions for patients and advance cancer care approaches will be presented – SOUTH … [Read more…]
